Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has reached a settlement agreement with MediLink Therapeutics and associated individuals to resolve disputes over alleged misappropriation of trade secrets and other civil litigations. The settlement involves MediLink sharing a portion of its income and profits from certain biopharmaceutical products with Sichuan Kelun-Biotech, which is expected to save time and costs for the company without adversely affecting its financial position or operations.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative therapies. The company operates in the biotechnology industry and is engaged in the research and production of biopharmaceutical products.
Average Trading Volume: 651,420
Technical Sentiment Signal: Buy
Current Market Cap: HK$102.3B
For detailed information about 6990 stock, go to TipRanks’ Stock Analysis page.